-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FP-045 in Cardiometabolic Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FP-045 in Cardiometabolic Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FP-045 in Cardiometabolic Disease Drug Details: FP-045 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garadacimab in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Idiopathic Pulmonary Fibrosis Drug Details: Garadacimab (CSL-312) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garadacimab in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Hereditary Angioedema (HAE)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Garadacimab in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Garadacimab in Interstitial Lung Diseases (Diffuse...
-
Product Insights
Likelihood of Approval Analysis for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Overview How likely is it that the drugs in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)...
-
Product Insights
Likelihood of Approval Analysis for Interstitial Lung Fibrosis
Overview How likely is it that the drugs in Interstitial Lung Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interstitial Lung Fibrosis Overview Interstitial Lung Fibrosis or interstitial lung disease...
-
Product Insights
Likelihood of Approval Analysis for Idiopathic Pulmonary Fibrosis
Overview How likely is it that the drugs in Idiopathic Pulmonary Fibrosis will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Idiopathic Pulmonary Fibrosis Overview Idiopathic pulmonary fibrosis (IPF), or (formerly) fibrosing...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Systemic Sclerosis (Scleroderma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Systemic Sclerosis (Scleroderma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Systemic Sclerosis (Scleroderma) Drug Details: efzofitimod (ATYR-1923) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efzofitimod in Interstitial Lung Diseases (Diffuse Parenchymal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imatinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imatinib in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib in Pulmonary Arterial Hypertension Drug Details: Imatinib (AER-901) is under...